1. Asadpour M, Pardal AH, Rajabian A, Abdollahi M. Investigation of fibrinogen and CRP changes following aspirin receipt in individuals with cardiovascular disease. PajoohandeJ. 2006.
2. Braith RW, Stewart KJ. Resistance exercise training: Its role in the prevention of cardiovascular disease. Circulation. 2006; 113(22): 2642-50. DOI:10.1161/CIRCULATIONAHA.105.584060. [
DOI:10.1161/CIRCULATIONAHA.105.584060]
3. McGrowder D, Riley CA, Morrison EYSt, Gordon L. The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer. Cholesterol. 2011; 2011: 496925. doi: 10.1155/2011/496925. [
DOI:10.1155/2011/496925]
4. Lunt H, Draper N, Marshall HC, Logan FJ, Hamlin MJ, Shearman JP, Cotter JD, et al. High Intensity Interval Training in a Real World Setting: A Randomized Controlled Feasibility Study in Overweight Inactive Adults, Measuring Change in Maximal Oxygen Uptake. PLoS ONE. 2014; 9(1): e 83256. doi:10.1371/journal.pone.0083256. [
DOI:10.1371/journal.pone.0083256]
5. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, et al. An investigation of serum concentration of APOM as a potential MODY3 marker using a novel ELISA. J Intern Med. 2010; 267 [
DOI:10.1111/j.1365-2796.2009.02145.x]
6. Xu N, Dahlback B. A Novel Human Apolipoprotein (APOM). J Biol Chem. 1999; 274: 31286-90. [
DOI:10.1074/jbc.274.44.31286]
7. Axler O, Ahnström J, Dahlbäck B. An Elisa For Apolipoprotein M Reveals A Strong Correlation To Total Cholesterol In Human Plasma. J Lipid Res. 2007; 48(8): 1772-80. [
DOI:10.1194/jlr.M700113-JLR200]
8. Ghanbari-Niaki A. Plasma Apolipoprotein-M (APOM) Response to a Circuit Resistance Training Program. Ann Appl Sport Sci. 2013; 1(4): 1-4.
9. Książek M, Charmas M, Klusiewicz A, Zabielski P, Długołęcka B, Chabowski A, et al. Endurance training selectively increases high-density lipoprotein-bound sphingosine-1-phosphate in the plasma. Scand J Med Sci Sports. 2018; 28(1): 57-64. [
DOI:10.1111/sms.12910]
10. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011; 108(23): 9613-8. doi: 10.1073/pnas.1103187108. [
DOI:10.1073/pnas.1103187108]
11. Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol. 2012; 10(4): 410-21. [
DOI:10.2174/157016112800812755]
12. Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis. 2008; 199(1): 19-26. [
DOI:10.1016/j.atherosclerosis.2007.10.007]
13. Baranowski M, Górski J, Klapcinska B, Waskiewicz Z, Sadowska-Krepa E. Ultramarathon run markedly reduces plasma sphingosine-1-phosphate concentration. Int J Sport Nutr Exerc Metab. 2014; 24(2): 148-56. doi: 10.1123/ijsnem.2013-0093. [
DOI:10.1123/ijsnem.2013-0093]
14. Baranowski M, Charmas M, Długołęcka B, Górski J. Exercise increases plasma levels of sphingoid base-1 phosphates in humans. Acta Physiol (Oxf). 2011;203(3):373-80. [
DOI:10.1111/j.1748-1716.2011.02322.x]
15. Nielsen LB, Christoffersen C, Ahnström J, Dahlbäck B. APOM: gene regulation and effects on HDL metabolism. Trends Endocrinol Metab. 2009; 20 [
DOI:10.1016/j.tem.2008.11.003]
16. Zhang X1, Mao S, Luo G, Wei J, Berggren-Söderlund M, Nilsson-Ehle P, Xu N. Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis. 2011 Jul 5;10:112. [
DOI:10.1186/1476-511X-10-112]
17. Mulya A, Seo J, Brown A, Gebre AK, Boudyguina E, Shelness G, et al. Apolipoprotein M Expression Increases The Size Of Nascent Preβ Hdl Formed By Atp Binding Cassette Transporter A1. J Lipid Res. 2010; 51(3): 514-524. doi: 10.1194/jlr.M002162. [
DOI:10.1194/jlr.M002162]
18. Di D, Wang Z, Liu Y, Luo G, Shi Y, Berggren-Söderlund M, Nilsson-Ehle P, et al. Abca1 Upregulating Apolipoproein M Expression Mediates Via The Rxr/Lxr Pathway In Hepg2 Cells. Biochem Biophys Res Commun.